R
Richard D. Carvajal
Researcher at Columbia University
Publications - 332
Citations - 28287
Richard D. Carvajal is an academic researcher from Columbia University. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 54, co-authored 282 publications receiving 23524 citations. Previous affiliations of Richard D. Carvajal include Cornell University & Kettering University.
Papers
More filters
Journal ArticleDOI
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.
Ben Tran,Richard D. Carvajal,Aurélien Marabelle,Aurélien Marabelle,Sandip Pravin Patel,Patricia LoRusso,Erik Rasmussen,Gloria Juan,Vijay V. Upreti,Courtney Beers,Gataree Ngarmchamnanrith,Patrick Schöffski +11 more
TL;DR: In patients with advanced solid tumors, AMG 228 Q3W was tolerable up to the highest tested dose (1200 mg), exhibited favorable pharmacokinetics, and provided target coverage indicating a pharmacokinetic profile appropriate for longer intervals, but there was no evidence of T-cell activation or anti-tumor activity with AMG 227 monotherapy.
Journal ArticleDOI
Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.
Brian A. Ginsberg,Humilidad F. Gallardo,Teresa S. Rasalan,Matthew Adamow,Zhenyu Mu,Sapna Tandon,Barrett B. Bewkes,Ruth-Ann Roman,Paul B. Chapman,Gary K. Schwartz,Richard D. Carvajal,Katherine S. Panageas,Stephanie L. Terzulli,Alan N. Houghton,Jianda Yuan,Jedd D. Wolchok +15 more
TL;DR: A comparable efficacy and safety profile was shown between the i.m. and PMED arms, despite a significantly decreased dose of DNA used for PMED injection.
Journal ArticleDOI
Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors
Dana E. Rathkopf,Mark A. Dickson,Darren R. Feldman,Richard D. Carvajal,Manish A. Shah,Nian Wu,Robert A. Lefkowitz,Mithat Gonen,Lauren M. Cane,H. Dials,Jennifer L. Winkelmann,George J. Bosl,Gary K. Schwartz +12 more
TL;DR: Encouraging results in the platinum-refractory germ cell tumor population has prompted a phase II trial that is currently open for accrual, and Flavopiridol with FOLFOX is a safe and tolerable regimen.
Proceedings ArticleDOI
Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors
Lillian L. Siu,Howard A. Burris,Dung T. Le,Antoine Hollebecque,Neeltje Steeghs,Jean-Pierre Delord,John Hilton,Bryan C. Barnhart,Emanuela Sega,Kinjal Sanghavi,Anke Klippel,Cyrus Hedvat,Ed Hilt,Mark Donovan,Adrianna Gipson,P. Basciano,Jennifer Postelnek,Yue Zhao,Raymond P. Perez,Richard D. Carvajal +19 more
TL;DR: Preliminary results of the first-in-human phase 1/2a study of BMS-986179 + nivolumab (NIVO) in patients (pts) with advanced solid tumors were well tolerated, with CD73 target engagement in the tumor and periphery and a safety profile similar to that of NIVO monotherapy.
Journal ArticleDOI
Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)
TL;DR: This study evaluating selumetinib in combination with dacarbazine was designed with input from the US FDA, and is the first potential registration trial to be conducted in patients with metastatic uveal melanoma.